SEMA4D and neoplasm: Moreover, Younis et al. showed that tumor cell-derived SEMA4D could polarize myeloid cells towards MDSC phenotype (CD33+,CD11b+,HLA-DR-/low), with a concomitant reduction in T cell proliferation and IFNγ production [23].